Anti-Apoptotic and Neurite-Protective Nanomedicine Augments Embryonic Stem Cells-Derived Retinal Ganglion Cell Transplantation in Glaucoma Recovery - PubMed
11 hours ago
- #glaucoma
- #retinal ganglion cells
- #nanomedicine
- The study focuses on retinal ganglion cell (RGC) degeneration as a primary cause of irreversible vision loss in glaucoma.
- A novel nanomedicine, lithium-epigallocatechin gallate nanoparticles (Li-EGCG NPs), is designed to enhance antioxidant capacity and neuroprotection.
- Li-EGCG NPs demonstrate broad-spectrum reactive oxygen species scavenging activity and biocompatibility with embryonic stem cell-derived RGCs (ESC-RGCs).
- In vitro, Li-EGCG NPs reduce oxidative stress-induced apoptosis, protect neurite integrity, and maintain mitochondrial homeostasis in ESC-RGCs.
- Transcriptomic analyses show activation of neuroprotective pathways, including apoptosis regulation, axon guidance, and mitochondrial function.
- In a retinal ischemia/reperfusion injury model, combining Li-EGCG NPs with ESC-RGCs transplantation improves ESC-RGC survival, preserves retinal structure, and restores visual function.
- The study highlights Li-EGCG NPs as a promising nanomedicine platform for retinal neurodegenerative diseases, enhancing cell-based therapies.